Literature DB >> 2910419

Sexual dysfunction and treatment for early stage cervical cancer.

L R Schover1, M Fife, D M Gershenson.   

Abstract

Assessment of sexual frequency, function, and behavior, as well as martial happiness and psychological distress was performed for 61 women with early stage, invasive cervical cancer at the time of diagnosis. Cancer treatment was radical hysterectomy alone for 26 women and radiotherapy with or without surgery for 37. Followups took place at 6 and 12 months after cancer therapy. Women's sexual satisfaction, capacity for orgasm, and frequency of masturbation remained stable, whereas frequency of sexual activity with a partner and range of sexual practices decreased significantly by one year. Women who received irradiation with or without surgery resembled women who underwent radical hysterectomy alone at 6 months. By one year, however, the radiotherapy group had developed dyspareunia, which was reflected in gynecologist ratings at pelvic examination. The women receiving radiotherapy also had more problems with sexual desire and arousal, and were less likely to resume several daily life activities. Cancer treatment modality was not related to marital happiness or stability, however.

Entities:  

Mesh:

Year:  1989        PMID: 2910419     DOI: 10.1002/1097-0142(19890101)63:1<204::aid-cncr2820630133>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

1.  Surviving gynecologic cancer and coping with sexual morbidity: an international problem.

Authors:  B.L. Andersen; J. van Der Does
Journal:  Int J Gynecol Cancer       Date:  1994-07       Impact factor: 3.437

2.  Chore or priority? Barriers and facilitators affecting dilator use after pelvic radiotherapy for gynaecological cancer.

Authors:  Carissa Bonner; Kathryn Nattress; Caroline Anderson; Jonathan Carter; Chris Milross; Shannon Philp; Ilona Juraskova
Journal:  Support Care Cancer       Date:  2011-12-08       Impact factor: 3.603

3.  Toward clinical care guidelines for supporting rehabilitative vaginal dilator use with women recovering from cervical cancer.

Authors:  Kimberley Cullen; Karen Fergus; Tracey DasGupta; Iwa Kong; Marg Fitch; Catherine Doyle; Lauran Adams
Journal:  Support Care Cancer       Date:  2013-02-17       Impact factor: 3.603

4.  Prospective study of vaginal dilator use adherence and efficacy following radiotherapy.

Authors:  Ethel Law; Joanne F Kelvin; Bridgette Thom; Elyn Riedel; Ashlyn Tom; Jeanne Carter; Kaled M Alektiar; Karyn A Goodman
Journal:  Radiother Oncol       Date:  2015-07-08       Impact factor: 6.280

Review 5.  Quality of life and gynecologic malignancies.

Authors:  Charlotte C Sun; Michael Frumovitz; Diane C Bodurka
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

6.  The impact of cervical cancer and dysplasia: a qualitative, multiethnic study.

Authors:  Kimlin T Ashing-Giwa; Marjorie Kagawa-Singer; Geraldine V Padilla; Judith S Tejero; Evana Hsiao; Rajinder Chhabra; Lucrecia Martinez; M Belinda Tucker
Journal:  Psychooncology       Date:  2004-10       Impact factor: 3.894

7.  No association between body size and frequency of sexual intercourse among oral contraceptive users.

Authors:  Larissa R Brunner Huber; Whitney A Stanley; Leah Broadhurst; Jacek Dmochowski; Tara M Vick; Delia Scholes
Journal:  Ann Epidemiol       Date:  2014-06-17       Impact factor: 3.797

8.  Sexuality and sexual function in long-term survivors of cervical cancer.

Authors:  Howard P Greenwald; Ruth McCorkle
Journal:  J Womens Health (Larchmt)       Date:  2008 Jul-Aug       Impact factor: 2.681

9.  Sexual self schema as a moderator of sexual and psychological outcomes for gynecologic cancer survivors.

Authors:  Kristen M Carpenter; Barbara L Andersen; Jeffrey M Fowler; G Larry Maxwell
Journal:  Arch Sex Behav       Date:  2008-04-17

10.  Enhancing physical well-being and overall quality of life among underserved Latina-American cervical cancer survivors: feasibility study.

Authors:  Kimlin T Ashing-Giwa
Journal:  J Cancer Surviv       Date:  2008-08-20       Impact factor: 4.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.